How to buy Incyte Corporation stock (INCY)

Incyte Corporation is a biotechnology business based in the US. Incyte Corporation shares (INCY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $67.55 – a decrease of 4.63% over the previous week. Incyte Corporation employs 2,524 staff and has a trailing 12-month revenue of around $4.1 billion.

Our top picks for where to buy Incyte Corporation stock

Buy Incyte Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Incyte Corporation stock price (NASDAQ: INCY)

Use our graph to track the performance of INCY stocks over time.

Incyte Corporation shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$67.55
52-week range	$50.35 - $83.95
50-day moving average more info button	$72.10
200-day moving average more info button	$63.20
Wall St. target price	$79.30
PE ratio more info button	750.5555
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.09

Is it a good time to buy Incyte Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Incyte Corporation price performance over time

Historical closes compared with the close of $69.4 from 2024-12-17

1 week (2024-12-12)	-2.02%
1 month (2024-11-20)	-2.32%
3 months (2024-09-19)	3.86%
6 months (2024-06-18)	12.96%

1 year (2023-12-19)	12.12%
2 years (2022-12-19)	-13.89%
3 years (2021-12-17)	72.89
5 years (2019-12-19)	91.14

Is Incyte Corporation stock undervalued or overvalued?

Valuing Incyte Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Incyte Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Incyte Corporation's P/E ratio

Incyte Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 751x. In other words, Incyte Corporation shares trade at around 751x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Incyte Corporation's PEG ratio

Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5921. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Incyte Corporation's EBITDA

Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $80.5 million.

The EBITDA is a measure of a Incyte Corporation's overall financial performance and is widely used to measure a its profitability.

Incyte Corporation financials

Revenue TTM	$4.1 billion
Operating margin TTM	14.96%
Gross profit TTM	$1.6 billion
Return on assets TTM	-0.12%
Return on equity TTM	0.8%
Profit margin	0.8%
Book value	$16.45
Market Capitalization more info button	$13 billion

TTM: trailing 12 months

Incyte Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Incyte Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Incyte Corporation's total ESG risk score

Total ESG risk: 29.4

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Incyte Corporation's overall score of 29.4 (as at 12/31/2018) is nothing to write home about – landing it in it in the 48th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Incyte Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Incyte Corporation's environmental score

Environmental score: 7.61/100

Incyte Corporation's environmental score of 7.61 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Incyte Corporation's social score

Social score: 24.73/100

Incyte Corporation's social score of 24.73 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Incyte Corporation's governance score

Governance score: 12.56/100

Incyte Corporation's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Incyte Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Incyte Corporation's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Incyte Corporation scored a 1 out of 5 for controversy – the highest score possible, reflecting that Incyte Corporation has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Incyte Corporation was last rated for ESG on: 2019-01-01.

Total ESG score	29.4
Total ESG percentile	47.86
Environmental score	7.61
Environmental score percentile	8
Social score	24.73
Social score percentile	8
Governance score	12.56
Governance score percentile	8
Level of controversy	1

Incyte Corporation share dividends

We're not expecting Incyte Corporation to pay a dividend over the next 12 months.

Have Incyte Corporation's shares ever split?

Incyte Corporation's shares were split on a 2:1 basis on 31 August 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Incyte Corporation shares which in turn could have impacted Incyte Corporation's share price.

Incyte Corporation share price volatility

Over the last 12 months, Incyte Corporation's shares have ranged in value from as little as $50.3498 up to $83.95. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incyte Corporation's is 0.71. This would suggest that Incyte Corporation's shares are less volatile than average (for this exchange).

Incyte Corporation overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.

Frequently asked questions

null
What percentage of Incyte Corporation is owned by insiders or institutions?
Currently 2.037% of Incyte Corporation shares are held by insiders and 97.712% by institutions. How many people work for Incyte Corporation?
Latest data suggests 2,524 work at Incyte Corporation. When does the fiscal year end for Incyte Corporation?
Incyte Corporation's fiscal year ends in December. Where is Incyte Corporation based?
Incyte Corporation's address is: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 What is Incyte Corporation's ISIN number?
Incyte Corporation's international securities identification number is: US45337C1027 What is Incyte Corporation's CUSIP number?
Incyte Corporation's Committee on Uniform Securities Identification Procedures number is: 45337C102